Update: Drug shortages business opportunity gains steam

I liked getting mail when I was a kid, and it's the same today. Thanks to all who wrote in support of my editorial last week on the possibility of a business opportunity: a drug manufacturing niche addressing ongoing shortages.

CEOs, presidents, the principal at a consulting and sourcing company and a VP for business strategy from companies in the U.S., U.K, Italy and China are among those who wrote. They offered pharma- or business-related services and insights--including help with the business plan and with making connections--or they expressed that the drug-shortage niche had occurred as a business opportunity to them, too.

Fortified with this support, I'm now plying my editorial sources for manufacturing, business, regulatory and IP to get their read.

More reports as developments arise. In the meantime, keep the e-mails coming. - George Miller

Suggested Articles

The FDA has slapped the parent of Dollar Tree stores with a warning letter saying some CMOs that made its OTC products were among the world's worst.

GSK expects Shingrix supplies to rise slightly in 2020, but the real "step change" will come in 2024 with a brand-new manufacturing facility.

Continuing its expansion efforts, Japan’s Fujifilm will make a major investment in its U.S. gene therapy operation in Texas.